Hypoxia-Inducible Factor 1α in Type 2 Diabetes Mellitus: Mechanisms and Therapeutic Perspectives

Type 2 diabetes mellitus (T2DM) is a global epidemic driven by chronic hyperglycemia, leading to severe microvascular and macrovascular complications. Hypoxia is a critical pathogenic factor, and hypoxia-inducible factor 1α (HIF-1α) serves as a central transcriptional regulator of cellular adaptation to low oxygen. This review examines the dual roles of HIF-1α in T2DM and its complications, including diabetic kidney disease, retinopathy, obesity-related insulin resistance, and impaired wound healing. HIF-1α exerts protective effects by enhancing glycolysis, reducing oxidative stress, and promoting angiogenesis, but it can also be detrimental by driving pathological neovascularization, fibrosis, and chronic inflammation. Its functional outcomes depend on tissue type, disease stage, and metabolic context, posing therapeutic challenges. Emerging pharmacologic strategies aim to fine-tune HIF-1α activity. A deeper understanding of the spatiotemporal regulation of HIF-1α signaling may inform more targeted therapeutic strategies, though considerable preclinical and clinical challenges remain.